Dudediligence.

enGene Therapeutics Inc

ENGNNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$15.3MOct ’24−$24.6MJan ’25−$25.8MApr ’25−$29.0MJul ’25−$37.9MOct ’25−$29.8MJan ’26−$30.2MApr ’26−$32.5MJul ’26
Fiscal years, by the month each ended
LineOct 2021Oct 2022Oct 2023Oct 2024Oct 2025
Operating incomenone on file−$19.4M−$26.1M−$62.3M−$123.2M
Net incomenone on file−$24.5M−$99.9M−$55.1M−$117.3M
Operating cash flownone on file−$17.6M−$24.7M−$48.3M−$99.2M
Free cash flownone on file−$17.7M−$25.1M−$49.2M−$100.7M
Cash$11.0M$20.4M$81.5M$173.0M$50.2M
Shares outstandingnone on file665.8K23.2M51.0M52.0M